



Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Yu-Pei Chen, MD¹; Nofisat Ismaila, MD²; Melvin L. K. Chua, MD PhD³; A. Dimitrios Colevas, MD⁴; Robert Haddad, MD⁵; Shao Hui Huang, MD, MRT(T)⁶; Joseph T. S. Wee, MD³; Alexander C. Whitley, MD⁷; Jun-Lin Yi, MD⁸; Sue S. Yom, MD⁹; Anthony T. C. Chan, MD¹⁰; Chao-Su Hu, MD¹¹; Jin-Yi Lang, MD¹²; Quynh-Thu Le, MD⁴; Anne W. M. Lee, MD¹³; Nancy Lee, MD¹⁴; Jin-Ching Lin, MD¹⁵; Brigitte Ma, MD¹⁰; Thomas J. Morgan, MR¹⁶; Jatin Shah, MD¹⁴; Ying Sun, MD¹; and Jun Ma, MD¹

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC).

METHODS The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations.

RESULTS The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options.

RECOMMENDATIONS Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC.

Additional information is available at www.asco.org/head-neck-cancer-guidelines.

J Clin Oncol 00. © 2021 by American Society of Clinical Oncology

ASSOCIATED CONTENT

Appendix

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on November 13, 2020 and published at ascopubs.org/journal/jco on January 6, 2021; DOI <https://doi.org/10.1200/JCO.20.03237>

Practice Guidelines Committee approval: October 29, 2020

Reprint Requests: 2318 Mill Road, Suite 800, Alexandria, VA 22314; guidelines@asco.org

INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with an extremely uneven geographic global distribution. Although NPC is fairly uncommon in many jurisdictions, it remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.^{1,2} The nonkeratinizing pathological subtype accounts for more than 95% of NPC cases in endemic areas, which is highly associated with Epstein-Barr virus (EBV) infection, whereas the keratinizing subtype constitutes < 20% of cases worldwide.² Despite the relatively lower radiotherapy (RT) sensitivity of the keratinizing compared with nonkeratinizing subtypes, NPC almost exclusively relies on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease. Precision in RT contour delineation, planning and delivery, and coordination between chemotherapy

and RT are paramount to achieve optimal outcomes for this patient population.

Given the complexity of this malignancy, practitioners will benefit from high-quality evidence-based clinical practice guidelines.³ This Chinese Society of Clinical Oncology (CSCO) and ASCO joint guideline seeks to highlight significant clinical questions about chemotherapy in combination with RT for the definitive treatment of stage II to IVA NPC, and to provide recommendations on these topics on the basis of published literature and expert panel consensus.

GUIDELINE QUESTIONS

This clinical practice guideline addresses five overarching clinical questions: (1) What are the recommended RT techniques and fractionation regimens for patients with stage II-IVA NPC? (2) What is the recommended chemotherapy sequence in addition to RT for patients with stage II-IVA NPC? (3) What are the recommended chemotherapy options for patients with

THE BOTTOM LINE

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: Chinese Society of Clinical Oncology and ASCO Guideline

Guideline Questions

1. What are the recommended radiotherapy techniques and fractionation regimens for patients with stage II-IVA nasopharyngeal carcinoma?
2. What is the recommended chemotherapy sequence in addition to radiotherapy for patients with stage II-IVA nasopharyngeal carcinoma?
3. What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy?
4. What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving induction chemotherapy?
5. What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving adjuvant chemotherapy?

Target Population

Patients with stage II-IVA nasopharyngeal carcinoma.

Target Audience

Medical oncologists, radiation oncologists, clinical oncologists, surgeons, nurses, pathologists, oncology pharmacists, and patients.

Methods

An expert panel was convened to develop clinical practice guideline recommendations on the basis of a systematic review of the medical literature.

Recommendations

Radiotherapy

For patients with stage II-IVA nasopharyngeal carcinoma.

Recommendation 1.1. For all patients with nasopharyngeal carcinoma (NPC), intensity-modulated radiotherapy (IMRT) with daily image guidance should be offered. If IMRT is unavailable, patients should be transferred to institutions that could implement IMRT whenever possible (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 1.2. For all patients with NPC, both sequential boost and simultaneous integrated boost radiotherapy may be offered (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 1.3. For all patients with NPC, a prescribed dose of 70 Gy in 33-35 fractions (2.0-2.12 Gy per fraction) delivered over 7 weeks (once daily, 5 fractions per week) should be offered. Radiation dose may be adjusted according to tumor volume and its response to (chemo-)radiotherapy (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 1.4. For all patients with NPC, gross tumor volume should be carefully delineated. Target delineation should follow consensus guidelines and exploit technical opportunities including image fusion. MRI image fusion with CT for target delineation is mandatory, especially to appreciate the potential tumor extension at the skull base and rule out or confirm the presence of cranial nerve involvement and/or intracranial extension (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Recommendation 1.5. For patients with NPC who have undergone induction chemotherapy, the preinduction scan should be fused with the postinduction CT simulation data set to illustrate the initial disease extent. The gross tumor volume should generally follow the preinduction tumor extent, especially within bony anatomy (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 1.6. The delineation of elective nodal volumes should follow international consensus guidelines and cover the bilateral neck from the retropharyngeal lymph nodes to level IV and V. Level 1b may be omitted in prophylactic volume unless there is involvement of the anterior half of the nasal cavity or if there are level II lymph nodes with extranodal extension or size > 2 cm or bilateral involvement. Omission of lower neck volume in the uninvolved side of the neck may be considered if the neck contains no equivocal lymph node(s) (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

(continued on following page)

THE BOTTOM LINE (CONTINUED)

Chemotherapy Sequence

Recommendation 2.1. For patients with T2N0 (AJCC 8th) NPC, chemotherapy is not routinely recommended, but may be offered if there are adverse features, such as bulky tumor volumes or high EBV DNA copy number (Type: evidence based; harms outweigh benefits; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 2.2. For patients with T1-2N1 (AJCC 8th) NPC, concurrent chemotherapy may be offered, particularly for T2 N1 patients (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 2.3. For patients with Stage III-IVA (except T3N0) (AJCC 8th) NPC, induction chemotherapy should be offered in addition to concurrent chemoradiotherapy (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 2.4. For patients with Stage III-IVA (except T3N0) (AJCC 8th) NPC who do not receive induction chemotherapy plus concurrent chemoradiotherapy, then concurrent chemoradiotherapy plus adjuvant chemotherapy should be offered (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

NOTE. There is a lack of head-to-head trials comparing induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy, thus which sequence performs better in the contemporary era remains uncertain.

Recommendation 2.5. For patients with T3N0 (AJCC 8th) NPC, concurrent chemoradiotherapy should be offered. Adjuvant or induction chemotherapy may also be offered (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Concurrent Chemotherapy

Recommendation 3.1. For all patients with NPC without contraindications, concurrent cisplatin, given weekly (40 mg/m²) or once every 3 weeks (triweekly) (100 mg/m², or at least 80 mg/m²), should be offered along with radiotherapy (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 3.2. For all patients with NPC without contraindications, in the concurrent chemotherapy setting, 3 doses of triweekly or 7 doses of weekly cisplatin should be attempted to achieve a cumulative dose of at least 200 mg/m² (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 3.3. For patients with NPC with a contraindication to cisplatin, nedaplatin (100 mg/m² triweekly) may be offered for concurrent chemoradiotherapy. Other options that may be offered are carboplatin (area under curve [AUC], 5-6 triweekly) or oxaliplatin (70 mg/m² weekly) (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Recommendation 3.4. For patients with NPC with a contraindication to platinum-based chemotherapy, fluoropyrimidines (eg, capecitabine, 5-fluorouracil, and tegafur) with concurrent radiotherapy may be offered (Type: evidence based; benefits outweigh harms; Evidence quality: low; Strength of recommendation: weak).

Induction Chemotherapy

Recommendation 4.1. For all patients with NPC receiving induction chemotherapy, platinum-based induction regimens should be offered. The following regimens may be used in the absence of medical contraindications: GP (gemcitabine: 1,000 mg/m² d1, d8; cisplatin 80 mg/m² d1) or TPF (docetaxel 60-75 mg/m² d1; cisplatin 60-75 mg/m² d1; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5); others include PF (cisplatin 80-100 mg/m² d1; 5-fluorouracil 800-1,000 mg/m² per day, continuous intravenous infusion d1-5), PX (cisplatin 100 mg/m² d1; capecitabine 2000 mg/m² per day, d1-14), and TP (docetaxel 75 mg/m² d1; cisplatin 75 mg/m² d1) (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Recommendation 4.2. For patients with NPC receiving induction chemotherapy, the regimens should be administered every three weeks for a total of three cycles, or at the minimum two cycles (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Recommendation 4.3. For patients with NPC receiving induction chemotherapy, chemoradiotherapy should be commenced within 21-28 days from the first day of the last cycle of induction chemotherapy (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Adjuvant Chemotherapy

Recommendation 5.1. For all patients with NPC receiving adjuvant chemotherapy, PF (cisplatin 80 mg/m² d1 or 20 mg/m² per day, d1-5; 5-fluorouracil 1,000 mg/m² per day, continuous intravenous infusion d1-4, or 800 mg/m² per day, continuous

(continued on following page)

THE BOTTOM LINE (CONTINUED)

intravenous infusion d1-5) administered every 4 weeks for a total of 3 cycles should be offered (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 5.2. For all patients with NPC receiving adjuvant chemotherapy and with a contraindication to cisplatin, carboplatin (AUC 5) may be combined with 5-fluorouracil (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 5.3. For all patients with NPC receiving adjuvant chemotherapy and with a contraindication to platinum-containing chemotherapy, the use of non-platinum-based regimens remains experimental at this time and should not be offered routinely outside the context of a clinical trial (Type: evidence based; harms outweigh benefits; Evidence quality: intermediate; Strength of recommendation: strong).

Additional Resources

More information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources, is available at www.asco.org/head-neck-cancer-guidelines. The Methodology Manual (available at www.asco.org/guideline-methodology) provides additional information about the methods used to develop this guideline. Patient information is available at www.cancer.net.

CSCO and ASCO believe that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.

NPC receiving concurrent chemoradiotherapy? (4) What are the recommended chemotherapy options for patients with NPC receiving induction chemotherapy? (5) What are the recommended chemotherapy options for patients with NPC receiving adjuvant chemotherapy?

METHODS

Guideline Development Process

This systematic review-based guideline product was developed by an international multidisciplinary expert panel, which included a patient representative and an ASCO guidelines staff member with health research methodology expertise. The expert panel included representatives from the CSCO, which was the lead organization on this joint effort. The expert panel, cochaired by J.M. and Y. S., met via teleconference and/or webinar and corresponded through e-mail. On the basis of the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. The guideline recommendations were sent for an open comment period of 2 weeks allowing the public to review and comment on the recommendations after submitting a confidentiality agreement. These comments were taken into consideration while finalizing the recommendations. Members of the expert panel were responsible for reviewing and approving the penultimate version of the guideline, which was then submitted to *Journal of Clinical Oncology (JCO)* for editorial review and consideration for publication. All ASCO guidelines are ultimately reviewed and approved by the expert panel and the ASCO Clinical Practice Guidelines Committee prior to publication. All funding for the administration of the project was provided by CSCO.

The recommendations were developed by using a systematic review in PubMed (January 1990 to August 2020) of

systematic reviews, meta-analyses, and randomized clinical trials (RCTs), and clinical experience. Articles were selected for inclusion in the systematic review of the evidence on the basis of the following criteria: (1) studies including patients with stage II-IVA NPC and (2) interventions focusing on RT and/or chemotherapy for definitive treatment.

Articles were excluded from the systematic review if they were (1) meeting abstracts not subsequently published in peer-reviewed journals; (2) editorials, commentaries, letters, news articles, case reports, narrative reviews; and (3) published in a non-English language. The guideline recommendations are crafted, in part, using the *Guidelines Into Decision Support (GLIDES)* methodology and accompanying BRIDGE-Wiz software.⁴ In addition, a guideline implementability review was conducted. On the basis of the implementability review, revisions were made to the draft to clarify recommended actions for clinical practice. Ratings for the type and strength of recommendation, evidence, and potential bias are provided with each recommendation.

The ASCO and CSCO expert panel and guidelines staff will work with coauthors to keep abreast of any substantive updates to the guideline. On the basis of the formal review of the emerging literature, ASCO and CSCO will determine the need to update. The ASCO Guidelines Methodology Manual (available at www.asco.org/guideline-methodology) provides additional information about the guideline update process. This is the most recent information as of the publication date.

Guideline Disclaimer

The Clinical Practice Guidelines and other guidance published herein are provided by the CSCO and ASCO, Inc, to assist providers in clinical decision making. The information herein should not be relied upon as being complete

or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating provider as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words such as must, must not, should, and should not indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. CSCO and ASCO provide this information on an as-is basis and makes no warranty, express or implied, regarding the information. CSCO and ASCO specifically disclaim any warranties of merchantability or fitness for a particular use or purpose. CSCO and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

Guideline and Conflicts of Interest

The expert panel was assembled in accordance with ASCO's Conflict of Interest Policy Implementation for Clinical Practice Guidelines ("Policy," found at <http://www.asco.org/rwc>). All members of the expert panel completed ASCO's disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting, or advisory role; speaker's bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the policy, the majority of the members of the expert panel did not disclose any relationships constituting a conflict under the Policy.

RESULTS

Characteristics of Studies Identified in the Literature Search

A total of 108 studies met eligibility criteria and form the evidentiary basis for the guideline recommendations.

These included 42 systematic reviews⁵⁻⁴⁶ and 66 RCTs.⁴⁷⁻¹¹² Identified trials were published between 1990 and August 2020 and focused on RT and/or chemotherapy. The primary outcomes reported in studies on therapeutic interventions included overall survival (OS), progression-free survival (PFS), relapse-free survival (RFS), failure-free survival (FFS), disease-free survival (DFS) as well as distant failure-free survival or control rate, locoregional failure-free survival or control rate, and quality of life. Of note, whereas many of the studies quoted in this article used the American Joint Committee on Cancer (AJCC) 6th or 7th editions, all references to stage in the recommendations in this guideline are based on the current 8th edition of the AJCC staging system.¹¹³ Details on the study characteristics are included in the Supplement (Data Supplement, online only). The systematic review flow diagram is shown in [Figure 1](#).

Study Quality Assessment

Study design aspects related to individual study quality, strength of evidence, strength of recommendations, and risk of bias were assessed. Study quality was formally assessed for the 66 RCTs identified. Design aspects related to the individual study quality were assessed by one reviewer, with factors such as blinding, allocation concealment, placebo control, intention to treat, funding sources, etc., generally indicating a low (30%), intermediate (59%), and high (11%) potential risk of bias for most of the identified evidence. Follow-up times varied between studies, lowering the comparability of the results. Refer to the ASCO Methodology Manual (<https://www.asco.org/research-guidelines/quality-guidelines/guidelines-tools-resources/guideline-methodology>) for more information and for definitions of ratings for overall potential risk of bias.

RECOMMENDATIONS

CLINICAL QUESTION 1

What are the recommended RT techniques and fractionation regimens for patients with stage II-IVA NPC?

Recommendation 1.1. For all patients with NPC, intensity-modulated radiotherapy (IMRT) with daily image guidance should be offered. If IMRT is unavailable, patients should be transferred to institutions that could implement IMRT whenever possible (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 1.2. For all patients with NPC, both sequential boost and simultaneous integrated boost radiotherapy may be offered (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Literature review and clinical interpretation. Compared with conventional 2-dimensional (2D) or 3-dimensional (3D) RT, IMRT enables conformation of tumoricidal doses to




FIG 1. PRISMA diagram.

irregular shaped distributions, thereby providing opportunities for safe delivery of high doses to NPC while protecting adjacent critical structures. The benefit of toxicity reduction with IMRT, such as neurotoxicity, xerostomia, trismus, and dysphagia, has been demonstrated in three RCTs^{80,92,95} and multiple meta-analyses.^{13,29} One RCT⁸⁰ and several meta-analyses have also shown that IMRT enhances disease control and survival in patients with NPC.^{11,13,29}

Daily image guidance should be implemented to minimize interfractional setup variation during high-precision radiotherapy. Daily image guidance may also enable customized margin for planning target volumes (PTV) and monitoring of geometric and dosimetric changes during the planned course of RT.¹¹⁴⁻¹¹⁸

IMRT can be delivered using either sequential boost or simultaneous integrated boost technique. A phase III RCT⁵⁷ of 209 patients has shown similar efficacy and toxicities with these two approaches. The former allows adaptation of treatment volume to a patient's anatomic changes. The latter is a convenient and resource-saving approach by maintaining a single treatment phase.

Recommendation 1.3. For all patients with NPC, a prescribed dose of 70 Gy in 33-35 fractions (2.0-2.12 Gy per fraction) delivered over 7 weeks (once daily, 5 fractions per week) should be offered. Radiation dose may be adjusted according to tumor volume and its response to (chemo-) radiotherapy (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Literature review and clinical interpretation. Outcomes of patients with NPC have improved significantly. However, NPC survivors often suffer from substantial toxicity burdens.¹¹⁹ RT fraction size is one of the major determinants of late toxicity. The fraction size of 2.0 to 2.12 Gy, five fractions per week, to a total prescribed dose of 70 Gy in 33-35 fractions was used in the Intergroup 0099¹¹⁰ and RTOG 0225 trials¹²⁰ and demonstrated good efficacy with acceptable toxicity. Since patients with residual disease have a poor prognosis,^{121,122} for a patient with MRI-detected residual tumor at the end of IMRT, an additional 2-4 Gy boost in 1-2 fractions may be considered. For a very responsive small primary, a slightly lower total dose (eg, 66-68 Gy) may be considered. Larger fraction sizes should be avoided, especially when combined with chemotherapy, because of concerns about substantial late toxicity with unproven efficacy. The Hong Kong NPC-9902^{96,123} and NPC-0501^{71,124} trials failed to demonstrate a clinical benefit from moderately accelerated fractionation of six fractions versus conventional fractionation of five fractions per week RT. The value of hyperfractionation with twice-daily fractions to increase the total dose while keeping the overall RT duration the same is uncertain in NPC since clinical trials show conflicting results.^{81,93,108}

Recommendation 1.4. For all patients with NPC, gross tumor volume should be carefully delineated. Target delineation should follow consensus guidelines and exploit technical opportunities including image fusion. MRI image

fusion with CT for target delineation is mandatory, especially to appreciate the potential tumor extension at the skull base and rule out or confirm the presence of cranial nerve involvement and/or intracranial extension (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Literature review and clinical interpretation. CT and MRI are both important for target delineation in this disease. MRI improves the detection of disease extension at the skull base, perineural disease without bone involvement, marrow infiltration, tumor extension to the paranasal sinuses and orbit, and retropharyngeal lymph node involvement, while CT improves the detection of neck disease and cortical bone invasion.^{125,126} The expert panel recommends to follow international consensus guidelines on target and organs at risk contouring¹²⁷⁻¹²⁹ and IMRT planning,¹³⁰ which emphasize the importance of MRI-CT image fusion in gross tumor volume (GTV) delineation, and provide guidance on clinical target volume (CTV) delineation¹²⁸ and dose prioritization and acceptance criteria in IMRT planning.¹³⁰ The radiation oncologist is encouraged to review the CT or MRI with a head and neck radiologist to appreciate the disease extent and if applicable, the response to induction chemotherapy (IC), especially when uncertainty is aroused.

Recommendation 1.5. For patients with NPC who have undergone induction chemotherapy, the preinduction scan should be fused with the postinduction CT simulation data set to illustrate the initial disease extent. The gross tumor volume should generally follow the preinduction tumor extent, especially within bony anatomy (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Literature review and clinical interpretation. The international consensus guidelines¹²⁸ recommend full therapeutic dose to cover preinduction gross tumor extent without exceeding the maximal tolerance of critical structures regardless of response to IC. This is especially important at the skull base because of the difficulty in fully appreciating the disease extent within bony anatomy, lack of salvage options in this location, and uncertain benefit from postinduction volume reduction. A phase III RCT by Yang et al⁵⁵ enrolled 212 patients with locally advanced NPC and compared efficacy and toxicities of patients treated with GTV delineated according to postinduction MRI (Post-IC GTV) versus those maintaining the preinduction volume (Pre-IC GTV). While the PTV of Post-IC GTV received 70 Gy in both arms, the PTV of Pre-IC GTV was randomly assigned to receive either 70 Gy in arm A or 64 Gy in arm B. There was no difference in disease control and survival between the two arms. Grade 4 late toxicity was also similar, but the group receiving 64 Gy to Pre-IC GTV had better xerostomia scores and better cognitive function. Therefore, carefully tailoring around the residual GTV after IC may be feasible if

the resolved preinduction GTV is fully covered with at least an intermediate dose.

Recommendation 1.6. The delineation of elective nodal volumes should follow international consensus guidelines and cover the bilateral neck from the retropharyngeal lymph nodes to level IV and V. Level 1b may be omitted in prophylactic volume unless there is involvement of the anterior half of the nasal cavity or if there are level II lymph nodes with extranodal extension or size > 2 cm or bilateral involvement. Omission of lower neck volume in the uninvolved side of the neck may be considered if the neck contains no equivocal lymph node(s) (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Literature review and clinical interpretation. NPC has a highly infiltrative nature within the nasopharyngeal mucosa. The CTV delineation should follow international consensus guidelines¹²⁸ with attention to any potential routes of spread. To reduce treatment toxicity, modifications of traditional elective volumes, such as sparing the level 1B nodal region or omitting lower neck volumes in the uninvolved side of the neck, have been explored in clinical trials and retrospective cohort studies. Two retrospective studies^{131,132} have shown that level 1b-sparing IMRT appears to be safe and feasible, with the exception of patients with level IIA lymph node \geq 2 cm and/or with extranodal extension, N2 disease, or primary tumor extension to areas that drain to level 1b as the first echelon site. The safety of lower neck sparing in uninvolved side of the neck was demonstrated in a meta-analysis,²¹ a small RCT for N0 patients,⁷⁶ and several retrospective studies.¹³³⁻¹³⁵

CLINICAL QUESTION 2

What is the recommended chemotherapy sequence in addition to radiotherapy for patients with stage II-IVA nasopharyngeal carcinoma?

Recommendation 2.1. For patients with T2N0 (AJCC 8th) NPC, chemotherapy is not routinely recommended, but may be offered if there are adverse features, such as bulky tumor volumes or high EBV DNA copy number (type: evidence-based; harms outweigh benefits; evidence quality: intermediate; strength of recommendation: moderate).

Recommendation 2.2. For patients with T1-2N1 (AJCC 8th) NPC, concurrent chemotherapy may be offered, particularly for T2 N1 patients (type: evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate).

Literature review and clinical interpretation. In the era of conventional 2D-RT, Chen et al⁸⁶ reported a randomized study showing significant improvements in 5-year OS and PFS in favor of concurrent chemoradiotherapy (CCRT) over RT alone for stage II NPC. The addition of concurrent chemotherapy reduced distant failure without a significant

improvement in locoregional control over RT alone. However, it should be noted that the study used the Chinese 1992 staging system, and 13% of patients would be reclassified as N2/stage III according to the 7th edition International Union Against Cancer/American Joint Committee on Cancer (UICC/AJCC) TNM classification criteria. The 10-year outcomes of this trial were in accordance with the previous report, but suggested that the survival benefits conferred by CCRT were mainly reflected in the T2N1 population.⁵¹ As IMRT has become a routine choice, the role of concurrent chemotherapy is not absolutely defined for stage II NPC, given the paucity of randomly assigned data in the IMRT era. Several meta-analyses,^{15,19,24} mainly including retrospective studies, have shown that IMRT alone may achieve equivalent treatment outcomes as compared to CCRT for stage II NPC. Recently, Huang et al⁴⁸ described the outcomes of a randomized phase II trial involving 84 patients with stage II NPC. With a median follow-up of 75 months, they observed no superiority of CCRT over IMRT alone for 5-year OS (94% v 100%; $P = .25$) and PFS (87% v 90%; $P = .72$). Considering that stage II consists of three subgroups (T2N0, and T1-2N1), among which N1 patients are at higher risk of distant metastasis,¹³⁶ the results of an ongoing large RCT (ClinicalTrials.gov Identifier: [NCT02633202](https://clinicaltrials.gov/ct2/show/study/NCT02633202)) evaluating additional concurrent chemotherapy to IMRT are anticipated to shed light on the appropriate treatment for this subset. Incorporating other prognosticators such as plasma EBV DNA^{137,138} may allow risk stratification of this heterogeneous group of patients with stage II NPC and permit optimal chemotherapy tailoring high-risk subset.

Recommendation 2.3. For patients with Stage III-IVA (except T3N0) (AJCC 8th) NPC, induction chemotherapy should be offered in addition to concurrent chemoradiotherapy (type: evidence-based; benefits outweigh harms; evidence quality: high; strength of recommendation: strong).

Recommendation 2.4. For patients with Stage III-IVA (except T3N0) (AJCC 8th) NPC who did not receive induction chemotherapy plus concurrent chemoradiotherapy, concurrent chemoradiotherapy plus adjuvant chemotherapy should be offered (type: evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate).

NOTE. There is a lack of head-to-head trials comparing induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy, thus which sequence performs better in the contemporary era remains uncertain.

Recommendation 2.5. For patients with T3N0 (AJCC 8th) NPC, concurrent chemoradiotherapy should be offered. Adjuvant or induction chemotherapy may also be offered (type: evidence-based; benefits outweigh harms; evidence

quality: intermediate; strength of recommendation: moderate).

Literature review and clinical interpretation. The landmark Intergroup 0099 randomized trial established chemoradiotherapy as the standard treatment of locoregionally advanced (stage III-IVA) NPC, given the superior survival end points of CCRT plus adjuvant chemotherapy (AC) over RT alone.¹¹⁰ Subsequent randomized studies from endemic areas confirmed the survival benefit of CCRT with or without AC versus RT alone in locoregionally advanced NPC.^{62,75,78,85,98,100-102} An individual patient data (IPD) meta-analysis of 19 RCTs showed that the most significant OS benefits of adding chemotherapy to RT were seen with CCRT either with or without AC.³⁷ By contrast, if without concurrent chemotherapy, AC or IC plus RT did not yield significant survival benefits as compared with RT alone. Therefore, CCRT is considered the backbone of treatment for locoregionally advanced NPC.

Notably, the Intergroup 0099 trial was conducted in the conventional RT era where locoregional failure dominated. In the IMRT era, patterns of failure have changed and excellent locoregional control has been achieved. Thus, the benefit of the addition of AC following CCRT for NPC becomes controversial. The primary results of a phase III randomized trial⁸⁴ revealed no significant difference in all outcome parameters in patients with locoregionally advanced NPC treated with CCRT alone versus CCRT plus AC, and the long-term results⁶³ confirmed these findings (5-year OS: 80% v 83%, $P = .35$; 5-year PFS: 71% v 75%, $P = .72$). In another phase III trial,⁶¹ 104 high-risk patients with NPC identified by detectable plasma EBV DNA after RT were randomly assigned to AC using gemcitabine and cisplatin for six cycles, or observation. That study is the first biomarker-driven RCT in NPC. There was neither OS nor PFS improvement with the addition of AC (5-year rate for OS: 64% v 68%; $P = .79$; for PFS: 49% v 55%; $P = .75$). Several network meta-analyses^{23,30,139,140} reported no statistically significant differences in treatment outcomes by adding AC to CCRT, although a favorable trend for CCRT plus AC was observed. The relatively poor tolerance of AC after definitive RT, with 50%-76% of patients typically completing planned AC,^{61,84,91,96,98,99,110} may account for the lack of observed benefit in NPC. The ongoing NRG-HN001 trial (ClinicalTrials.gov Identifier: [NCT02135042](https://clinicaltrials.gov/ct2/show/study/NCT02135042)) uses post-RT plasma EBV DNA to select candidates for AC and may identify subgroups who may benefit from the addition of AC on the basis of post-RT risk stratification. Metronomic use of capecitabine in AC is also being investigated in a phase III RCT (ClinicalTrials.gov Identifier: [NCT02958111](https://clinicaltrials.gov/ct2/show/study/NCT02958111)).

Compared with AC, IC offers several potential advantages, such as earlier relief of symptoms, better tolerance, early eradication of micrometastases, and tumor volume reduction for sparing critical structures.^{2,44} However, early

randomized studies^{69,83,89} comparing CCRT with or without IC did not consistently demonstrate favorable results regarding additional IC, probably because of the different induction regimens used or insufficient sample size. In recent years, three large-scale multicenter RCTs^{49,50,52,64,66} from Guangzhou were reported; the trials used induction docetaxel, cisplatin, and 5-fluorouracil (TPF)^{52,66}; cisplatin and 5-fluorouracil (PF)^{50,64}; and gemcitabine and cisplatin (GP)⁴⁹ regimens, respectively. These studies all confirmed the superiority of the addition of IC to CCRT over CCRT alone for OS, PFS, and distant failure-free survival, whereas locoregional failure-free survival was improved only in the long-term results of the TPF trial.^{52,66} An IPD pooled analysis of four aforementioned trials from endemic areas^{50,52,64,66,69,89} demonstrated that IC plus CCRT significantly improved OS (hazard ratio [HR], 0.75; 95% CI, 0.57 to 0.99; 6% absolute benefit at 5 years) and PFS (HR, 0.70; 95% CI, 0.56 to 0.86; 9% absolute benefit at 5 years), with the survival benefit mainly resulting from reduced distant failure (HR, 0.68; 95% CI, 0.51 to 0.90; 7% absolute reduction).²² A small randomized study from Tunisia and France enrolled 83 patients with locoregionally advanced NPC, and also showed improved PFS with the addition of induction TPF, with a significant effect on OS.⁶⁰ Therefore, IC plays an important role in addition to CCRT in management of locoregionally advanced NPC in the IMRT era, mainly through improvement in distant control translating into survival benefit.

Nevertheless, it should be noted that most trials evaluating additional IC to CCRT were conducted in endemic areas; the applicability of IC in nonendemic patients with NPC warrants further studies. Besides, which chemotherapy sequence, that is, induction-concurrent or concurrent-adjuvant, performs better in the contemporary era remains uncertain because of a paucity of prospective randomized trial data directly comparing the two approaches. It is only by inferential comparison of trials with CCRT as the control that IC seems to outperform AC in reduction of distant metastasis in patients with locoregionally advanced NPC. In the subgroup analyses of the NPC-0501 trial by Lee et al,^{47,71} comparison of IC plus CCRT versus CCRT plus AC in the conventional fractionation group suggested a significant benefit for 5-year OS (84% v 72%; $P = .042$) and PFS (78% v 62%; $P = .015$) after adjusting for multiple comparisons. A network meta-analysis evaluating the survival benefit of chemoradiotherapy regimens between 2D- or 3D-RT and IMRT²³ showed that IC followed by concurrent IMRT ranked first in probability for OS, PFS, and distant failure-free survival, whereas AC following concurrent IMRT ranked first in probability for locoregional failure-free survival, although no statistically significant differences in these outcomes were observed between the two groups. Future head-to-head trials comparing IC plus CCRT and CCRT plus AC are needed.

As compared to other patients with locoregionally advanced disease, patients with T3N0 NPC have a relatively lower risk

of treatment failure.¹³⁸ This subgroup was therefore excluded from several RCTs assessing the addition of AC^{63,84} or IC to CCRT.^{49,50,52,64,66} Given the lack of randomized trial data, the expert panel recommends a detailed discussion of the benefits versus harms of adding AC or IC to CCRT for T3N0 patients.^{137,138,141}

CLINICAL QUESTION 3

What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy?

Recommendation 3.1. For all patients with NPC without contraindications, concurrent cisplatin, given weekly (40 mg/m²) or triweekly (100 mg/m², or at least 80 mg/m²), should be offered along with RT (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 3.2. For all patients with NPC without contraindications, in the concurrent chemotherapy setting, 3 doses of triweekly or 7 doses of weekly cisplatin should be attempted to achieve a cumulative dose of at least 200 mg/m² (Type: informal consensus; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Recommendation 3.3. For patients with NPC with a contraindication to cisplatin, nedaplatin (100 mg/m² triweekly) may be offered for concurrent chemoradiotherapy. Other options that may be offered are carboplatin (area under curve [AUC] 5-6 triweekly) or oxaliplatin (70 mg/m² weekly) (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).

Recommendation 3.4. For patients with NPC with a contraindication to platinum-based chemotherapy, fluoropyrimidines (eg, capecitabine, 5-fluorouracil, and tegafur) with concurrent RT may be offered (Type: evidence based; benefits outweigh harms; Evidence quality: low; Strength of recommendation: weak),

Literature review and clinical interpretation. The recommendations of triweekly cisplatin of 100 mg/m² or weekly cisplatin of 40 mg/m² dosing to be delivered concurrently with RT were based on the early randomized phase III trials comparing CCRT with or without AC versus RT alone.^{62,78,86,98,100,110} These trials established the superiority of chemoradiotherapy over RT for locoregionally advanced NPC. Of note, three trials^{62,98,110} used the triweekly regimen, whereas two trials^{78,100} used the weekly regimen; one trial by Chen et al⁸⁶ used weekly cisplatin of 30 mg/m² for 7 cycles. Head-to-head comparisons between both regimens have been performed. A small randomized phase II study by Lee et al⁶⁷ showed no significant differences in efficacy and toxicity profiles between the once weekly (40 mg/m²) and triweekly (100 mg/m²) schedules of cisplatin, and the weekly cisplatin regimen appeared to be associated with improved quality of life. Likewise, a large-

scale phase III RCT ([ClinicalTrials.gov](https://clinicaltrials.gov) Chinese Clinical Trial Register identifier: ChiCTR-TRC-12001979) enrolled 526 patients with locoregionally advanced NPC, and the preliminary results suggested no difference in survival outcomes, but there were increased incidences of leukopenia (27.3% v16.2%) and thrombocytopenia (4.8% v1.2%) for the weekly regimen (40 mg/m² × 6) compared with the triweekly (100 mg/m² × 2) schedule.¹⁴² The final results of that study may aid complete assessment of the different dosing schedules. Of note, the total dose in the triweekly schedule was lower (200 mg/m²) compared with the weekly regimen (240 mg/m²).

Evidence, however, suggests that the cumulative dose of cisplatin may play a more important role than cisplatin schedule for efficacy. In this regard, no level 1 data exist to guide the optimal dose intensity of concurrent cisplatin, although post hoc analyses of phase III trials suggest that a threshold of cumulative dose of 200 mg/m² is required for efficacy.^{17,123,143} If IC is given in addition to CCRT, retrospective data show that the cumulative cisplatin dose needed in CCRT phase is typically 160 mg/m² on the basis of patient tolerance of cumulative cisplatin.¹⁴⁴⁻¹⁴⁶ For patients in whom cisplatin is contraindicated, other alternative concurrent agents include carboplatin (area under the curve [AUC] 5-6),^{87,94,147} oxaliplatin (70 mg/m² weekly),⁹⁷ and nedaplatin (100 mg/m² triweekly).⁵⁶ If platinum-based chemotherapy is contraindicated, fluoropyrimidines such as UFT (uracil and tegafur in a 4:1 M ratio)¹⁰¹ may also be offered as an option.

CLINICAL QUESTION 4

What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving induction chemotherapy?

Recommendation 4.1. For all patients with NPC receiving induction chemotherapy, platinum-based induction regimens should be offered. The following regimens may be used in the absence of medical contraindications: GP (gemcitabine: 1,000 mg/m² d1, d8; cisplatin 80 mg/m² d1) or TPF (docetaxel 60-75 mg/m² d1; cisplatin 60-75 mg/m² d1; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5); others include PF (cisplatin 80-100 mg/m² d1; 5-fluorouracil 800-1,000 mg/m² per day, continuous intravenous infusion d1-5), PX (cisplatin 100 mg/m² d1; capecitabine 2000 mg/m² per day, d1-14), and TP (docetaxel 75 mg/m² d1; cisplatin 75 mg/m² d1) (type: evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: strong).

Literature review and clinical interpretation. A 2009 published randomized phase II study⁸⁹ first observed significant improvement in 3-year OS from 68% to 94% (HR, 0.24; 95% CI, 0.08 to 0.73) by adding two cycles of induction docetaxel (75 mg/m²) and cisplatin (75 mg/m²) before CCRT in NPC. Subsequently, two large-scale phase III RCTs^{49,52,66} demonstrated the efficacy of induction TPF

(60 mg/m² docetaxel, 60 mg/m² cisplatin, and 600 mg/m² 5-fluorouracil as a continuous 120-hour infusion; every 3 weeks for three cycles) and GP (1,000 mg/m² gemcitabine on days 1 and 8, and 80 mg/m² cisplatin; every 3 weeks for three cycles) in locoregionally advanced NPC (except T3-4N0), respectively. In the TPF trial,^{52,66} the 5-year OS (HR, 0.65; 95% CI, 0.43 to 0.98), PFS (HR, 0.65; 95% CI, 0.43 to 0.98), distant failure-free survival (HR, 0.60; 95% CI, 0.38 to 0.95), and locoregional failure-free survival (HR, 0.58; 95% CI, 0.34 to 0.99) were all significantly improved in the IC plus CCRT group as compared to the CCRT alone group. Despite the 20% dose reduction of each drug compared with that in another trial (75 mg/m² docetaxel, 75 mg/m² cisplatin, and 750 mg/m² 5-fluorouracil as a continuous 120-hour infusion),⁶⁰ a high incidence of grade 3 or 4 acute toxicities such as neutropenia (35%), leukopenia (27%), and diarrhea (8%) was observed. In the other trial,⁴⁹ the induction GP regimen also showed benefits for 3-year OS (HR, 0.43; 95% CI, 0.24 to 0.77), PFS (HR, 0.51; 95% CI, 0.34 to 0.77), and distant failure-free survival (HR, 0.43; 95% CI, 0.25 to 0.73), but locoregional control was not significantly improved. Relatively good tolerance was shown for GP, with incidence of grade 3 or 4 neutropenia, leukopenia, and diarrhea of 21%, 11%, and 0.4%, respectively. Other recommended induction regimens included PF (80-100 mg/m² cisplatin and 800-1,000 mg/m² 5-fluorouracil as a continuous 120-hour infusion) and cisplatin plus capecitabine (PX; 100 mg/m² cisplatin and 2000 mg/m² capecitabine daily for 14 days).^{47,50,64,71}

There is a paucity of randomly assigned data comparing different induction regimens directly. A recent randomized, noninferiority trial enrolling 278 patients with locoregionally advanced NPC suggested similar treatment efficacy of the TPF and PF regimens.¹⁴⁸ The indirect comparisons of an IPD meta-analysis detected no significant differences between different IC regimens, that is, such as TPF, TP, and PF,²² whereas another IPD network meta-analysis of 28 trials involving 8,214 patients indicated that IC with taxanes ranked better than IC without taxanes for OS, although no statistically significant difference was shown.¹⁴⁹ Therefore, the IC regimen could be selected based on the patient's status. Whether replacing cisplatin with other platinum agents such as lobaplatin or nedaplatin or replacing 5-fluorouracil with capecitabine during the induction phase can maintain noninferior efficacy with improved quality of life is under evaluation ([ClinicalTrials.gov](https://clinicaltrials.gov) clinical trial information: ChiCTR-TRC-13003285, [NCT03503136](https://clinicaltrials.gov)).

Recommendation 4.2. For patients with NPC receiving induction chemotherapy, the regimens should be administered every 3 weeks for a total of 3 cycles, or at the minimum 2 cycles (type: evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: strong).

Recommendation 4.3. For patients with NPC receiving induction chemotherapy, chemoradiotherapy should be commenced within 21-28 days from the first day of the last cycle of induction chemotherapy (type: informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate).

Literature review and clinical interpretation. Two or three cycles of IC are recommended, and three cycles are more commonly used, although there are no randomly assigned data on the efficacy of different cycles. A retrospective study suggested that additional cycles to two cycles of IC were not associated with improved treatment outcomes for patients with NPC.⁴⁷ Real-time monitoring of EBV DNA during IC may also inform on tumor response for therapeutic adaptation,⁴⁸ but more prospective data are warranted. Given the absence of prospective literature evaluating the impact of the interval between IC and RT on survival in NPC, the expert panel recommends that patients should start RT within 3-4 weeks from the first day of the last IC cycle to minimize the risk of treatment failure. This is supported by a retrospective analysis that reported that a prolonged interval > 30 days was associated with unfavorable prognosis.⁴⁹

CLINICAL QUESTION 5

What are the recommended chemotherapy options for patients with nasopharyngeal carcinoma receiving adjuvant chemotherapy?

Recommendation 5.1. For all patients with NPC receiving adjuvant chemotherapy, PF (cisplatin 80 mg/m² d1 or 20 mg/m² per day, d1-5; 5-fluorouracil 1,000 mg/m² per day, continuous intravenous infusion d1-4, or 800 mg/m² per day, continuous intravenous infusion d1-5) administered every 4 weeks for a total of 3 cycles should be offered (Type: evidence based; benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Literature review and clinical interpretation. Results of the Intergroup study set a standard of three cycles AC with PF (cisplatin 80 mg/m² on day 1 and 5-fluorouracil 1,000 mg/m² on days 1-4, continuous 96-hour infusion, repeated every 4 weeks) after definitive CCRT.¹¹⁰ Several large randomized trials confirmed the superiority of CCRT plus AC to RT alone for locoregionally advanced NPC.^{62,78,85,98} Both drugs can be delivered with minor modification without changing the dose intensity, that is, dividing cisplatin dose of 80 mg/m² over 4 consecutive days (20 mg/m² day 1-4) by the Singapore group² or changing 5-fluorouracil administration from a daily dose of 1,000 mg/m² for 4-day continuous infusion to a daily dose of 800 mg/m² for 5-day infusion by the Guangzhou group.^{78,84} These modifications are intended to reduce the acute toxicities of the regimen. Of note, the original design of PF regimen in head and neck cancer was cisplatin 100 mg/m² on day 1 and 5-fluorouracil 1,000 mg/m² on days 1-5, continuous 120-hour infusion, repeated every 3 weeks in the neoadjuvant setting.¹⁵⁰ In consideration of poor tolerance to

adjuvant therapy after definitive CCRT in NPC, this regimen was adjusted with not only a 20% reduction of dose intensity for both drugs but also changing delivery schedule from every 3 weeks to every 4 weeks per cycle in all these trials. Despite these modifications, only 55% of patients could complete the planned three cycles of AC in the Intergroup study,¹¹⁰ and a range of 46%-78% completion rate was reported in other trials.^{62,71,78,84,85,98,120} The pooled data of 441 patients with locoregionally advanced NPC treated in the Hong Kong trials NPC-9901 and NPC-9902 showed that the total dose of 5-fluorouracil during AC was significantly associated with the distant failure-free rate by multivariate analysis.¹⁵¹ Thus, current evidence recommends completing three cycles of PF regimen for patients who need adjuvant therapy by an experienced team.

Recommendation 5.2. For all patients with NPC receiving adjuvant chemotherapy and with a contraindication to cisplatin, carboplatin (AUC 5) may be combined with 5-fluorouracil (Type: evidence based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).

Literature review and clinical interpretation Replacing cisplatin with carboplatin is also acceptable if cisplatin is contraindicated.^{94,152} A single-center randomized, non-inferiority trial compared the Intergroup regimen above to carboplatin infusion of 100 mg/m² concurrent with RT followed by carboplatin (AUC 5 intravenously) and 5-fluorouracil (100 mg/m²/day over 96 hours) in 206 patients with NPC. Forty-two percent of patients in the cisplatin group completed the three cycles of AC compared with 73% in the carboplatin group. Similar survival outcomes were shown; nephrotoxicity, leukopenia, and anemia were more common in the cisplatin group, whereas thrombocytopenia was more common in the carboplatin arm. The same group also conducted a multicenter randomized trial to compare concurrent chemoradiation with carboplatin to the same regimen with adjuvant carboplatin and 5-fluorouracil in 175 patients with T2N0-T4N2M0 NPC (UICC/AJCC 7th edition).¹⁵² The addition of adjuvant carboplatin-fluorouracil resulted in significantly improved 2-year disease-free survival.

Recommendation 5.3. For all patients with NPC receiving adjuvant chemotherapy and with a contraindication to platinum-containing chemotherapy, the use of non-platinum-based regimens remains experimental at this time and should not be offered routinely outside the context of a clinical trial (Type: evidence based; harms outweigh benefits; Evidence quality: intermediate; Strength of recommendation: strong).

Literature review and clinical interpretation. CCRT plus AC remains an option for locoregionally advanced NPC. While IC improved distant control, CCRT plus AC had superior local control presumably from accelerated repopulation associated with induction strategies.¹⁵³⁻¹⁵⁹

In the NPC-0501 trial,^{71,124} induction PF showed no significant differences with adjuvant PF, despite the higher doses, dose density, and better tolerability of IC, whereas the induction cisplatin-capecitabine arm performed better. Several retrospective studies reported significant OS improvements with a metronomic oral fluorouracil drug as AC.¹⁶⁰⁻¹⁶³ Metronomic chemotherapy refers to treatment at regular intervals with substantially lower doses over prolonged periods.¹⁶⁴ The high compliance and low toxicities of metronomic chemotherapy render this strategy appealing for AC in patients with NPC after completing radical CCRT. A phase 3 trial of metronomic adjuvant capecitabine has completed the accrual (ClinicalTrials.gov identifier: [NCT02958111](#)), whereas another testing UFT is ongoing (ClinicalTrials.gov identifier: [NCT02363400](#)). As aforementioned, the main criticism of AC is tolerability. Metronomic oral fluorouracil or the use of other drug regimens as AC may address this issue. Besides, alternative treatment options for platinum unsuitable patients were provided in other head and neck cancers¹⁶⁵; but the current use of non-platinum-based regimens remains experimental in NPC, and cannot be routinely recommended.

Figure 2 provides visual interpretations of these recommendations in the management algorithm.

PATIENT AND CLINICIAN COMMUNICATION

Several retrospective studies have identified a survival benefit in patients with NPC treated in high-volume institutions.¹⁶⁶⁻¹⁶⁸ The improvement likely reflects the availability of expertise and resources (medication, equipment, and personnel), protocol adherence, peer-reviewed quality assurance processes, as well as multidisciplinary coordination and supportive care in these institutions. For a clinician who is not familiar with the management of NPC or a facility lacking such resources, it is encouraged to seek expert advice or to refer the patient to an institution with expertise and resources available to deliver high-precision (chemo-)radiotherapy, including institutions beyond their local or regional area of residence. For recommendations and strategies to optimize patient-clinician communication, see Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline.¹⁶⁹

HEALTH DISPARITIES

Although this CSCO and ASCO clinical practice guideline represents expert recommendations on the best practices in disease management to provide the highest level of cancer care, it is important to note that many patients have limited access to medical care. Racial and ethnic disparities in health care contribute significantly to this problem in the United States. Patients with cancer who are members of racial or ethnic minorities suffer

disproportionately from comorbidities, experience more substantial obstacles to receiving care, are more likely to be uninsured, and are at greater risk of receiving care of poor quality than other Americans.¹⁷⁰⁻¹⁷³ All over the world, many patients lack access to care because of their geographic location and distance from appropriate treatment facilities. Awareness of these disparities in access to care should be considered in the context of this clinical practice guideline, and healthcare providers should strive to deliver the highest level of cancer care to these vulnerable populations.

MULTIPLE CHRONIC CONDITIONS

Creating evidence-based recommendations to inform treatment of patients with additional chronic conditions, a situation in which the patient may have two or more such conditions—referred to as multiple chronic conditions (MCC)—is challenging. Patients with MCC are a complex and heterogeneous population, making it difficult to account for all the possible permutations to develop specific recommendations for care. In addition, the best available evidence for treating index conditions, such as cancer, is often from clinical trials whose study selection criteria may exclude these patients to avoid potential interaction effects or confounding of results associated with MCC. As a result, the reliability of outcome data from these studies may be limited, thereby creating constraints for expert groups to make recommendations for care in this heterogeneous patient population.

As many patients for whom guideline recommendations apply present with MCC, any treatment plan needs to take into account the complexity and uncertainty created by the presence of MCC and highlights the importance of shared decision making regarding guideline use and implementation. Therefore, in consideration of recommended care for the target index condition, clinicians should review all other chronic conditions present in the patient and take those conditions into account when formulating the treatment and follow-up plan.

In light of these considerations, practice guidelines should provide information on how to apply the recommendations for patients with MCC, perhaps as a qualifying statement for recommended care. This may mean that some or all of the recommended care options are modified or not applied, as determined by best practice in consideration of any MCC.

COST IMPLICATIONS

Increasingly, individuals with cancer are required to pay a larger proportion of their treatment costs through deductibles and coinsurance.^{174,175} Higher patient out-of-pocket costs have been shown to be a barrier to initiating and adhering to recommended cancer treatments.^{176,177}




FIG 2. Treatment algorithm of stage II-IVA nasopharyngeal carcinoma. ^aThere is a lack of head-to-head trials comparing induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy. AJCC, American Joint Committee on Cancer; AUC, area under curve; civ, continuous intravenous infusion; EBV, Epstein-Barr virus; FU, fluorouracil; IMRT, intensity-modulated radiotherapy; NPC, nasopharyngeal carcinoma; SEQ-IMRT, sequential IMRT; SIB-IMRT, simultaneous integrated boost IMRT.

Discussion of cost can be an important part of shared decision making.¹⁷⁸ Clinicians should discuss with patients the use of less expensive alternatives when it is practical and feasible for treatment of the patient's disease and there are two or more treatment options that are comparable in terms of benefits and harms.¹⁷⁸

Patient out-of-pocket costs may vary depending on insurance coverage. Coverage may originate in the medical or pharmacy benefit, which may have different cost-sharing arrangements. Patients should be aware of the fact that different products may be preferred or covered by their particular insurance plan. Even with the same insurance plan, the price may vary between different pharmacies. When discussing financial issues and concerns, patients should be made aware of any financial counseling services available to address this complex and heterogeneous landscape.¹⁷⁸

As part of the guideline development process, CSCO and ASCO may opt to search the literature for published cost-effectiveness analyses that might inform the relative

value of available treatment options. Excluded from consideration are cost-effective analyses that lack contemporary cost data; agents that are not currently available in either China or the United States or Canada; and/or are industry-sponsored. No cost-effectiveness analyses were identified to inform the topic.

EXTERNAL REVIEW AND OPEN COMMENT

The draft recommendations were released to the public for open comment from August 10, 2020, through August 24, 2020. Response categories of "Agree as written," "Agree with suggested modifications," and "Disagree. See comments" were captured for every proposed recommendation with forty written comments received from 13 respondents. Most of the responses received either agreed or agreed with slight modifications to the recommendations and few of the respondents disagreed. Expert panel members reviewed comments from all sources and determined whether to maintain original draft recommendations, revise with minor language changes, or consider major recommendation

revisions. All changes were incorporated prior to CPGC review and approval.

GUIDELINE IMPLEMENTATION

This CSCO and ASCO guideline is developed for implementation across health settings. A member from ASCO's Practice Guideline Implementation Network (PGIN) is included on the panel. The additional role of this PGIN representative on the guideline panel is to assess the suitability of the recommendations to implementation in the community setting, but also to identify any other barrier to implementation a reader should be aware of. Barriers to implementation include the need to increase awareness of the guideline recommendations among frontline practitioners and survivors of cancer and caregivers, and also to provide adequate services in the face of limited resources. The guideline Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely through the ASCO PGIN. Specifically, cochairs from CSCO are responsible for the implementation of this guideline in China. Finally, it should be noted that majority of the studies included in this guideline are from endemic regions, and future trials are warrant to confirm the applicability of the recommendations to nonendemic patients with NPC. ASCO guidelines are posted on the ASCO website and most often published in the *Journal of Clinical Oncology*.

CSCO and ASCO believe that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.

AFFILIATIONS

¹Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, and Chinese Society of Clinical Oncology, Beijing, People's Republic of China

²American Society of Clinical Oncology, Alexandria, VA

³National Cancer Centre Singapore/Duke-NUS Medical School, Singapore

⁴Stanford University School of Medicine, Stanford, CA

⁵Dana-Farber Cancer Institute, Boston, MA

⁶Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada

⁷Central Alabama Radiation Oncology, Montgomery, AL

⁸National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, and Chinese Society of Clinical Oncology, Beijing, People's Republic of China

⁹University of California San Francisco, San Francisco, CA

¹⁰State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China

¹¹Fudan University Shanghai Cancer Center, Shanghai, and Chinese Society of Clinical Oncology, Beijing, People's Republic of China

¹²Sichuan Cancer Hospital & Institute, Chengdu, and Chinese Society of Clinical Oncology, Beijing, People's Republic of China

ADDITIONAL RESOURCES

More information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources, is available at www.asco.org/head-neck-cancer-guidelines. Patient information is available at www.cancer.net.

RELATED ASCO GUIDELINES

- Integration of Palliative Care into Standard Oncology Practice¹⁷⁹ (<http://ascopubs.org/doi/10.1200/JCO.2016.70.1474>)
- Patient-Clinician Communication¹⁶⁹ (<http://ascopubs.org/doi/10.1200/JCO.2017.75.2311>)
- Role of Treatment Deintensification in the Management of p16 + Oropharyngeal Cancer¹⁸⁰ (<http://ascopubs.org/doi/10.1200/JCO.19.00441>)
- Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx¹⁸¹ (<http://ascopubs.org/doi/10.1200/JCO.18.01921>)
- Human Papillomavirus Testing in Head and Neck Carcinomas¹⁸² (<http://ascopubs.org/doi/10.1200/JCO.18.00684>)
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck¹⁸³ (<http://ascopubs.org/doi/10.1200/JCO.20.00275>)

¹³The University of Hong Kong—Shenzhen Hospital, People's Republic of China, and The University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China

¹⁴Memorial Sloan Kettering Cancer Center, New York, NY

¹⁵Changhua Christian Hospital, Changhua, Taiwan

¹⁶Patient Representative, Monmouth, NJ

CORRESPONDING AUTHOR

Jun Ma, MD, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, and Chinese Society of Clinical Oncology, 651 Dongfeng Road East, Guangzhou 510060, People's Republic of China; e-mail: majun2@mail.sysu.edu.cn.

EDITOR'S NOTE

This Chinese Society of Clinical Oncology (CSCO) and American Society of Clinical Oncology (ASCO) Joint Clinical Practice Guideline provides recommendations, with comprehensive review and analyses of the relevant literature for each recommendation. Additional information, including a supplement with additional evidence tables, slide sets, clinical tools and resources, and links to patient information at www.cancer.net, is available at www.asco.org/head-neck-cancer-guidelines.

EQUAL CONTRIBUTION

J.M. and Y.S. were expert panel coauthors.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.20.03237>.

AUTHOR CONTRIBUTIONS

Conception and design: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The expert panel wishes to thank Drs Harold Lau and Pavan Reddy and the Clinical Practice Guidelines Committee for their thoughtful reviews and insightful comments on this guideline.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68:394-424, 2018
- Chen YP, Chan ATC, Le QT, et al: Nasopharyngeal carcinoma. *Lancet* 394:64-80, 2019
- Chen YP, Wang YQ, Li WF, et al: Critical evaluation of the quality and recommendations of clinical practice guidelines for nasopharyngeal carcinoma. *J Natl Compr Canc Netw* 15:336-344, 2017
- Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. *J Am Med Inform Assoc* 19:94-101, 2012
- Zhou R, Zhu J, Chen X, et al: The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A meta-analysis. *Clin Transl Oncol* 22:429-439, 2020
- Wang P, Zhang M, Ke C, et al: The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 99:e19360, 2020
- Wang BC, Xiao BY, Lin GH, et al: The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: A systematic review and meta-analysis. *BMC Cancer* 20:393, 2020
- Zhang B, Li MM, Chen WH, et al: Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. *JAMA Netw Open* 2:e1913619, 2019
- Wang C, Wang F, Min X, et al: Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: An updated meta-analysis. *J Int Med Res* 47:2832-2847, 2019
- OuYang PY, Zhang XM, Qiu XS, et al: A pairwise meta-analysis of induction chemotherapy in nasopharyngeal carcinoma. *Oncologist* 24:505-512, 2019
- Luo MS, Huang GJ, Liu HB: Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma: A meta-analysis. *Medicine (Baltimore)* 98:e15951, 2019
- Li L, Liang W, Zhu JX, et al: Evolutionary role of chemotherapy in advanced nasopharyngeal carcinoma: A literature-based network meta-analysis. *Cancer Manag Res* 11:501-512, 2019
- Du T, Xiao J, Qiu Z, et al: The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. *PLoS One* 14:e0219611, 2019
- Yuan C, Xu XH, Luo SW, et al: Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?: A network meta-analysis. *Medicine (Baltimore)* 97:e11978, 2018
- Wang S, Li S, Shen L: Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature. *Curr Probl Cancer* 42:302-318, 2018
- Tan TH, Soon YY, Cheo T, et al: Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. *Radiother Oncol* 129:10-17, 2018
- Ng WT, Tung SY, Lee V, et al: Concurrent-adjuvant chemoradiation therapy for stage III-IVB nasopharyngeal carcinoma-exploration for achieving optimal 10-year therapeutic ratio. *Int J Radiat Oncol Biol Phys* 101:1078-1086, 2018
- Liu M, You W, Song YB, et al: The changing role of chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A updated systemic review and network meta-analysis. *Front Oncol* 8:597, 2018
- Liu F, Jin T, Liu L, et al: The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. *PLoS One* 13:e0194733, 2018
- He Y, Guo T, Guan H, et al: Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A meta-analysis. *Cancer Manag Res* 10:1419-1428, 2018
- Co JL, Mejia MBA, Dizon JMR: Evidence on effectiveness of upper neck irradiation versus whole neck irradiation as elective neck irradiation in node-negative nasopharyngeal cancer: A meta-analysis. *J Glob Oncol* 4:1-11, 2018
- Chen YP, Tang LL, Yang Q, et al: Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials. *Clin Cancer Res* 24:1824-1833, 2018
- You R, Cao YS, Huang PY, et al: The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two/three-dimensional radiotherapy to intensity-modulated radiotherapy: A network meta-analysis. *Theranostics* 7:4825-4835, 2017
- Xu C, Zhang LH, Chen YP, et al: Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: A systemic review and meta-analysis of 2138 patients. *J Cancer* 8:287-297, 2017
- Ribassin-Majed L, Marguet S, Lee AWM, et al: What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. *J Clin Oncol* 35:498-505, 2017
- He J, Wu P, Tang Y, et al: Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: A network meta-analysis. *Oncotarget* 8:39782-39794, 2017
- Yu H, Gu D, He X, et al: The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: A Bayesian network meta-analysis of published randomized controlled trials. *Onco Targets Ther* 9:159-170, 2016

28. Wang M, Tian H, Li G, et al: Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials. *Oncotarget* 7:48375-48390, 2016
29. Co J, Mejia MB, Dizon JM: Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature. *Head Neck* 38:E2130-E2142, 2016(suppl 1)
30. Yan M, Kumachev A, Siu LL, et al: Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. *Eur J Cancer* 51:1570-1579, 2015
31. Wang Y, Ding W, Chen C, et al: Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. *J Cancer Res Ther* 11:C191-C195, 2015(suppl 2)
32. Song Y, Wang W, Tao G, et al: Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma—A time-to-event meta-analysis. *Oral Oncol* 51:764-769, 2015
33. He X, Xu K, Guo J, et al: A meta-analysis of neoadjuvant chemotherapy plus radiation in the treatment of locally advanced nasopharyngeal carcinoma. *J Cancer Res Ther* 11:C205-C208, 2015(suppl 2)
34. Du CR, Ying HM, Kong FF, et al: Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: A meta-analysis based on randomized controlled trials. *Radiat Oncol* 10:70, 2015
35. Chen YP, Wang ZX, Chen L, et al: A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. *Ann Oncol* 26:205-211, 2015
36. Chen YP, Guo R, Liu N, et al: Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis of randomized controlled trials. *J Cancer* 6:883-892, 2015
37. Blanchard P, Lee A, Marguet S, et al: Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis. *Lancet Oncol* 16:645-655, 2015
38. Chen X, Hong Y, Feng J, et al: Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment. *Chin Med J (Engl)* 127:142-149, 2014
39. OuYang PY, Xie C, Mao YP, et al: Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. *Ann Oncol* 24:2136-2146, 2013
40. Liang ZG, Zhu XD, Tan AH, et al: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Meta-analysis of 1,096 patients from 11 randomized controlled trials. *Asian Pac J Cancer Prev* 14:515-521, 2013
41. Liang ZG, Zhu XD, Zhou ZR, et al: Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of 793 patients from 5 randomized controlled trials. *Asian Pac J Cancer Prev* 13: 5747-5752, 2012
42. Zhang L, Zhao C, Ghimire B, et al: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: A meta-analysis of the phase III randomized trials. *BMC Cancer* 10:558, 2010
43. Baujat B, Audry H, Bourhis J, et al: Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. *Int J Radiat Oncol Biol Phys* 64:47-56, 2006
44. Chua DT, Ma J, Sham JS, et al: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. *J Clin Oncol* 23:1118-11124, 2005
45. Langendijk JA, Leemans CR, Buter J, et al: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. *J Clin Oncol* 22:4604-4612, 2004
46. Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials. *Am J Clin Oncol* 25:219-223, 2002
47. Lee AWM, Ngan RKC, Ng WT, et al: NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. *Cancer* 126:3674-3688, 2020
48. Huang X, Chen X, Zhao C, et al: Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: A phase 2 multicenter clinical trial. *Front Oncol* 10:1314, 2020
49. Zhang Y, Chen L, Hu GQ, et al: Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. *N Engl J Med* 381:1124-1135, 2019
50. Yang Q, Cao SM, Guo L, et al: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase III multicentre randomised controlled trial. *Eur J Cancer* 119:87-96, 2019
51. Li XY, Chen QY, Sun XS, et al: Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. *Eur J Cancer* 110:24-31, 2019
52. Li WF, Chen NY, Zhang N, et al: Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. *Int J Cancer* 145:295-305, 2019
53. Kong XY, Lu JX, Yu XW, et al: Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: A prospective, multi-institution, randomized controlled phase II study. *Cancer Chemother Pharmacol* 84:155-161, 2019
54. Jin T, Qin WF, Jiang F, et al: Cisplatin and fluorouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyngeal carcinoma. *Transl Oncol* 12:633-639, 2019
55. Yang H, Chen X, Lin S, et al: Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. *Radiother Oncol* 126:37-42, 2018
56. Tang LQ, Chen DP, Guo L, et al: Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: An open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol* 19:461-473, 2018
57. Lerbtutsayanukul C, Prayongrat A, Kannarunimit D, et al: A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. *Strahlenther Onkol* 194:375-385, 2018
58. Hong RL, Hsiao CF, Ting LL, et al: Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. *Ann Oncol* 29:1972-1979, 2018
59. Gou XX, Jin F, Wu WL, et al: Induction chronomodulated chemotherapy plus radiotherapy for nasopharyngeal carcinoma: A phase II prospective randomized study. *J Cancer Res Ther* 14:1613-1619, 2018
60. Frikha M, Auperin A, Tao Y, et al: A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). *Ann Oncol* 29:731-736, 2018

61. Chan ATC, Hui EP, Ngan RKC, et al: Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial. *J Clin Oncol* 31:3091-3100, 2018
62. Lee AWM, Tung SY, Ng WT, et al: A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. *Cancer* 123:4147-4157, 2017
63. Chen L, Hu CS, Chen XZ, et al: Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. *Eur J Cancer* 75:150-158, 2017
64. Cao SM, Yang Q, Guo L, et al: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. *Eur J Cancer* 75:14-23, 2017
65. Tang C, Wu F, Wang R, et al: Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase II clinical trial. *Am J Cancer Res* 6:2064-2075, 2016
66. Sun Y, Li WF, Chen NY, et al: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. *Lancet Oncol* 17:1509-1520, 2016
67. Lee JY, Sun JM, Oh DR, et al: Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). *Radiother Oncol* 118:244-250, 2016
68. Wen L, You C, Lu X, et al: Phase II trial of concurrent chemoradiotherapy with S-1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma. *Mol Clin Oncol* 3:687-691, 2015
69. Tan T, Lim WT, Fong KW, et al: Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 91:952-960, 2015
70. Songthong AP, Kannarunimit D, Chakkabat C, et al: A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. *Radiat Oncol* 10:166, 2015
71. Lee AW, Ngan RK, Tung SY, et al: Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. *Cancer* 121:1328-1338, 2015
72. Kong F, Cai B, Lin S, et al: Assessment of radiotherapy combined with adjuvant chemotherapy in the treatment of patients with advanced nasopharyngeal carcinoma: A prospective study. *J BUON* 20:206-211, 2015
73. Huang PY, Zeng Q, Cao KJ, et al: Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. *Eur J Cancer* 51:1760-1770, 2015
74. Xu T, Zhu G, He X, et al: A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: Updated long-term survival outcomes. *Oral Oncol* 50:71-76, 2014
75. Wu X, Huang PY, Peng PJ, et al: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. *Ann Oncol* 24:2131-2136, 2013
76. Li JG, Yuan X, Zhang LL, et al: A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma. *Cancer* 119:3170-3176, 2013
77. Gu MF, Liu LZ, He LJ, et al: Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. *Int J Cancer* 132:215-223, 2013
78. Chen Y, Sun Y, Liang SB, et al: Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. *Cancer* 119:2230-2238, 2013
79. Xu T, Hu C, Zhu G, et al: Preliminary results of a phase III randomized study comparing chemotherapy neoadjuvantly or concurrently with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Med Oncol* 29:272-278, 2012
80. Peng G, Wang T, Yang KY, et al: A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. *Radiother Oncol* 104:286-293, 2012
81. Pan ZQ, He XY, Guo XM, et al: A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma. *Am J Clin Oncol* 35:600-605, 2012
82. Huang PY, Cao KJ, Guo X, et al: A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Oral Oncol* 48:1038-1044, 2012
83. Fountzilas G, Ciuleanu E, Bobos M, et al: Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. *Ann Oncol* 23:427-435, 2012
84. Chen L, Hu CS, Chen XZ, et al: Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial. *Lancet Oncol* 13:163-171, 2012
85. Lee AW, Tung SY, Chan AT, et al: A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. *Radiother Oncol* 98:15-22, 2011
86. Chen QY, Wen YF, Guo L, et al: Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: Phase III randomized trial. *J Natl Cancer Inst* 103:1761-1770, 2011
87. Lu X, Guo X, Hong MH, et al: Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal carcinoma: Docetaxel plus carboplatin versus 5-fluorouracil plus carboplatin. *Chin J Cancer* 29:140-144, 2010
88. Lee AW, Tung SY, Chua DT, et al: Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 102:1188-1198, 2010
89. Hui EP, Ma BB, Leung SF, et al: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. *J Clin Oncol* 27:242-249, 2009
90. Huang PY, Mai HQ, Luo DH, et al: Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Ai Zheng* 28:1033-1042, 2009
91. Chen Y, Liu MZ, Liang SB, et al: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. *Int J Radiat Oncol Biol Phys* 71:1356-1364, 2008
92. Kam MK, Leung SF, Zee B, et al: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. *J Clin Oncol* 25:4873-4879, 2007

93. Daoud J, Toumi N, Siala W, et al: Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma. *Radiother Oncol* 85:17-23, 2007
94. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al: Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial. *Eur J Cancer* 43:1399-1406, 2007
95. Pow EH, Kwong DL, McMillan AS, et al: Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. *Int J Radiat Oncol Biol Phys* 66:981-991, 2006
96. Lee AW, Tung SY, Chan AT, et al: Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 66:142-151, 2006
97. Zhang L, Zhao C, Peng PJ, et al: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results. *J Clin Oncol* 23:8461-8468, 2005
98. Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. *J Clin Oncol* 23:6730-6738, 2005
99. Lee AW, Lau WH, Tung SY, et al: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. *J Clin Oncol* 23:6966-6975, 2005
100. Chan AT, Leung SF, Ngan RK, et al: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 97:536-539, 2005
101. Kwong DL, Sham JS, Au GK, et al: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. *J Clin Oncol* 22:2643-2653, 2004
102. Lin JC, Jan JS, Hsu CY, et al: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. *J Clin Oncol* 21:631-637, 2003
103. Hareyama M, Sakata K, Shirato H, et al: A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. *Cancer* 94:2217-2223, 2002
104. Chi KH, Chang YC, Guo WY, et al: A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. *Int J Radiat Oncol Biol Phys* 52:1238-1244, 2002
105. Chan AT, Teo PM, Ngan RK, et al: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. *J Clin Oncol* 20:2038-2044, 2002
106. Ma J, Mai HQ, Hong MH, et al: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. *J Clin Oncol* 19:1350-1357, 2001
107. Chua DT, Sham JS, Choy D, et al: Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: The Queen Mary Hospital experience. *Int J Radiat Oncol Biol Phys* 49:1219-1228, 2001
108. Teo PM, Leung SF, Chan AT, et al: Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. *Int J Radiat Oncol Biol Phys* 48:1311-1312, 2000
109. Chua DT, Sham JS, Choy D, et al: Preliminary report of the Asian-Oceania Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceania Clinical Oncology Association Nasopharynx Cancer Study Group. *Cancer* 83:2270-2283, 1998
110. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. *J Clin Oncol* 16:1310-1317, 1998
111. International Nasopharynx Cancer Study Group, Trial VI: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. *Int J Radiat Oncol Biol Phys* 35:463-469, 1996
112. Chan AT, Teo PM, Leung TW, et al: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 33:569-577, 1995
113. Amin MB, Edge SB, American Joint Committee on Cancer: AJCC Cancer Staging Manual. Chicago, IL, American Joint Committee on Cancer, 2017
114. Zhang S, Zhou X, Zhang Q, et al: Analysis of setup error based on CTVision for nasopharyngeal carcinoma during IGRT. *J Appl Clin Med Phys* 17:15-24, 2016
115. Tan W, Wang Y, Yang M, et al: Analysis of geometric variation of neck node levels during image-guided radiotherapy for nasopharyngeal carcinoma: Recommended planning margins. *Quant Imaging Med Surg* 8:637-647, 2018
116. Shueng PW, Shen BJ, Wu LJ, et al: Concurrent image-guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. *Radiat Oncol* 6:95, 2011
117. Duma MN, Kampfer S, Schuster T, et al: Do we need daily image-guided radiotherapy by megavoltage computed tomography in head and neck helical tomotherapy? The actual delivered dose to the spinal cord. *Int J Radiat Oncol Biol Phys* 84:283-288, 2012
118. Liu J, Lyman KM, Ding Z, et al: Assessment of the therapeutic accuracy of cone beam computed tomography-guided nasopharyngeal carcinoma radiotherapy. *Oncol Lett* 18:1071-1080, 2019
119. McDowell L, Corry J, Ringash J, et al: Quality of life, toxicity and unmet needs in nasopharyngeal cancer survivors. *Front Oncol* 10:930, 2020
120. Lee N, Harris J, Garden AS, et al: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II trial 0225. *J Clin Oncol* 27:3684-3690, 2009
121. Lv JW, Zhou GQ, Li JX, et al: Magnetic resonance imaging-detected tumor residue after intensity-modulated radiation therapy and its association with post-radiation plasma Epstein-Barr virus deoxyribonucleic acid in nasopharyngeal carcinoma. *J Cancer* 8:861-869, 2017
122. He Y, Zhou Q, Shen L, et al: A retrospective study of the prognostic value of MRI-derived residual tumors at the end of intensity-modulated radiotherapy in 358 patients with locally-advanced nasopharyngeal carcinoma. *Radiat Oncol* 10:89, 2015
123. Lee AW, Tung SY, Ngan RK, et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 trials. *Eur J Cancer* 47:656-666, 2011
124. Lee AWM, Ngan RKC, Ng WT, et al: NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. *Cancer* 126:3674-3688, 2020
125. Manavis J, Sivridis L, Koukourakis MI: Nasopharyngeal carcinoma: The impact of CT-scan and of MRI on staging, radiotherapy treatment planning, and outcome of the disease. *Clin Imaging* 29:128-133, 2005
126. Liao XB, Mao YP, Liu LZ, et al: How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? *Int J Radiat Oncol Biol Phys* 72:1368-1377, 2008

127. Brouwer CL, Steenbakkers RJ, Bourhis J, et al: CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCR1, NRG oncology and TROG consensus guidelines. *Radiother Oncol* 117:83-90, 2015
128. Lee AW, Ng WT, Pan JJ, et al: International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiother Oncol* 126:25-36, 2018
129. Sun Y, Yu XL, Luo W, et al: Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. *Radiother Oncol* 110:390-397, 2014
130. Lee AW, Ng WT, Pan JJ, et al: International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 105:567-580, 2019
131. Ou X, Miao Y, Wang X, et al: The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels. *Radiat Oncol* 12:137, 2017
132. Zhang F, Cheng YK, Li WF, et al: Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: A retrospective analysis. *BMC Cancer* 15:709, 2015
133. Gao Y, Zhu G, Lu J, et al: Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma? *Int J Radiat Oncol Biol Phys* 77:1397-402, 2010
134. Tang LL, Tang XR, Li WF, et al: The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement. *Oral Oncol* 69:68-73, 2017
135. Xiao F, Dou S, Li Y, et al: Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes. *Clin Transl Oncol* 21:781-789, 2019
136. Tang LL, Chen YP, Mao YP, et al: Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. *J Natl Compr Canc Netw* 15:913-919, 2017
137. Lee VH, Kwong DL, Leung TW, et al: The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. *Int J Cancer* 144:1713-1722, 2019
138. Guo R, Tang LL, Mao YP, et al: Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. *Cancer* 125:79-89, 2019
139. Chen YP, Wang ZX, Chen L, et al: A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. *Ann Oncol* 26:205-211, 2015
140. Ribassin-Majed L, Marguet S, Lee AW, et al: What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. *J Clin Oncol* 35:498-505, 2016
141. Hui EP, Li WF, Ma BB, et al: Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. *Ann Oncol* 31:769-779, 2020
142. Liang H, Li WX, Lv X, et al: Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979). *J Clin Oncol* 35, 2017
143. Peng H, Chen L, Zhang Y, et al: Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase III clinical trial. *Oncologist* 21:1369-1376, 2016
144. Lv JW, Qi ZY, Zhou GQ, et al: Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. *Cancer Sci* 109:751-763, 2018
145. Liu SL, Sun XS, Yan JJ, et al: Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. *Radiother Oncol* 137:83-94, 2019
146. Wen DW, Li ZX, Chen FP, et al: Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy. *Oral Oncol* 107:104675, 2020
147. Huang PY, Zeng Q, Cao KJ, et al: Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. *Eur J Cancer* 51:1760-1770, 2015
148. Jin T, Qin W-f, Jiang F, et al: Cisplatin and fluorouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyngeal carcinoma. *Transl Oncol* 12:633-639, 2019
149. Petit C, Lee AWM, Carmel A, et al: Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients. *J Clin Oncol* 38:6523-6523, 2020
150. Rooney M, Kish J, Jacobs J, et al: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. *Cancer* 55:1123-1128, 1985
151. Lee AWM, Tung SY, Ngan RKC, et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. *Eur J Cancer* 47:656-666, 2011
152. Chitapanarux I, Kittichest R, Tungkasmit T, et al: Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial. *Curr Probl Cancer* 10.1016/j.cupr.2020.100620 [epub ahead of print on July 18, 2020]
153. Tang SQ, Xu C, Wang XS, et al: Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. *Oral Oncol* 105:104686, 2020
154. Setakornnukul J, Thephamongkhol K: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus chemotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. *BMC Cancer* 18:329, 2018
155. Ahn YC, Kim YS: Korean perspectives of nasopharynx cancer management. *Chin Clin Oncol* 5:28, 2016
156. Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. *Ann Oncol* 15:1179-1186, 2004
157. Peters LJ, Withers HR: Applying radiobiological principles to combined modality treatment of head and neck cancer—the time factor. *Int J Radiat Oncol Biol Phys* 39:831-836, 1997
158. Milas L, Nakayama T, Hunter N, et al: Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. *Radiother Oncol* 30:247-253, 1994
159. Bourhis J, Wilson G, Wibault P, et al: Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. *Laryngoscope* 104:468-472, 1994
160. Twu CW, Wang WY, Chen CC, et al: Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. *Int J Radiat Oncol Biol Phys* 89:21-29, 2014
161. Liu YC, Wang WY, Twu CW, et al: Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. *Oral Oncol* 64:15-21, 2017

162. Chen JH, Huang WY, Ho CL, et al: Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. *Head Neck* 41:3775-3782, 2019
163. Wang WY, Lin TY, Twu CW, et al: Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA. *Oncotarget* 7:42608-42616, 2016
164. Bocci G, Kerbel RS: Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect. *Nat Rev Clin Oncol* 13:659-673, 2016
165. Ahn MJ, D'Cruz A, Vermorken JB, et al: Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. *Oral Oncol* 53:10-16, 2016
166. Verma V, Allen PK, Simone CB II, et al: Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer. *JAMA Otolaryngol Head Neck Surg* 144:86-89, 2018
167. Lai TY, Yeh CM, Hu YW, et al: Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy. *Radiother Oncol* 151:190-199, 2020
168. Yoshida EJ, Luu M, David JM, et al: Facility volume and survival in nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 100:408-417, 2018
169. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology Consensus Guideline. *J Clin Oncol* 35:3618-3632, 2017
170. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2013. Bethesda, MD, National Cancer Institute, 2016. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site
171. American Cancer Society: Cancer Facts and Figures for African Americans 2016-2018. Atlanta, GA, American Cancer Society, 2016. <http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-047403.pdf>
172. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2015. www.cdc.gov/uscs
173. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
174. Schnipper LE, Davidson NE, Wollins DS, et al: Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. *J Clin Oncol* 34:2925-2934, 2016
175. Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. *J Clin Oncol* 33:2563-2577, 2015
176. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. *J Clin Oncol* 32:306-311, 2014
177. Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. *J Oncol Pract* 7:46s-51s, 2011
178. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. *J Clin Oncol* 27:3868-3874, 2009
179. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 35:96-112, 2017
180. Adelstein DJ, Ismaila N, Ku JA, et al: Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. *J Clin Oncol* 37:1578-1589, 2019
181. Koyfman SA, Ismaila N, Crook D, et al: Management of the neck in squamous cell carcinoma of the oral cavity and Oropharynx: ASCO clinical practice guideline. *J Clin Oncol* 37:1753-1774, 2019
182. Fakhry C, Lacchetti C, Rooper LM, et al: Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the College of American Pathologists Guideline. *J Clin Oncol* 36:3152-3161, 2018
183. Maghami E, Ismaila N, Alvarez A, et al: Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. *J Clin Oncol* 38:2570-2596, 2020



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: Chinese Society of Clinical Oncology and ASCO Guideline**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Nofisat Ismaila

Employment: GlaxoSmithKline (I)

Stock and Other Ownership Interests: GlaxoSmithKline (I)

Melvin L. K. Chua

Stock and Other Ownership Interests: Varian Medical Systems

Honoraria: Janssen Oncology, Ferring, Varian Medical Systems

Consulting or Advisory Role: Janssen Oncology, Illumina, Merck Sharp & Dohme, ImmunoSCAPE

Speakers' Bureau: AstraZeneca, Bayer, Pfizer

Research Funding: Varian Medical Systems, Ferring, PVmed, Decipher Biosciences

Travel, Accommodations, Expenses: Varian Medical Systems,

(OPTIONAL) Uncompensated Relationships: Alice Arc

A. Dimitrios Colevas

Consulting or Advisory Role: ATARA Biotherapeutics, Cue Biopharma, Inc., Pfizer DSMB, IQVIA RDS, Inc, PRA Health Sciences, IQVIA Biotech

Research Funding: Innate Pharma, CellSight Technologies, Inc, Tessa Therapeutics, Exelixis, NIH/NCI, Cullinan, Atara, AbbVie

Robert Haddad

Employment: Dana-Farber Cancer Institute

Leadership: NCCN

Consulting or Advisory Role: Celgene, Merck, Eisai, Bristol Myers Squibb, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics, GlaxoSmithKline, Vaccinex, EMD Serono, BioNTech AG

Research Funding: Boehringer Ingelheim, Merck, Bristol Myers Squibb, Celgene, AstraZeneca, VentiRx, Genentech, Pfizer, Kura

Alexander C. Whitley

Consulting or Advisory Role: Novocure, AstraZeneca

Speakers' Bureau: AstraZeneca, Novocure

Travel, Accommodations, Expenses: Novocure

Sue S. Yom

Research Funding: Genentech, Merck, Bristol Myers Squibb, BioMimetix

Patents, Royalties, Other Intellectual Property: UpToDate, Springer

Anthony T. C. Chan

Honoraria: Merck Sharp & Dohme, Merck Serono, Cullinan Management Inc., Merck

Consulting or Advisory Role: Merck Sharp & Dohme, Merck Serono, Cullinan Management Inc.

Research Funding: Pfizer, Merck Sharp & Dohme, Merck Serono, Lilly, Novartis, Boehringer Ingelheim

Travel, Accommodations, Expenses: Pfizer, Merck Sharp & Dohme, Roche, Bristol Myers Squibb, Novartis, AstraZeneca

Quynh-Thu Le

Stock and Other Ownership Interests: Aldea

Consulting or Advisory Role: GRAIL

Travel, Accommodations, Expenses: Genentech, Merck

Nancy Lee

Consulting or Advisory Role: Merck, Pfizer, Merck Serono, Sanofi

Research Funding: AstraZeneca, Pfizer

Jin-Ching Lin

Travel, Accommodations, Expenses: Taiwan Merck, Ono Pharmaceutical, MSD Oncology

Brigette Ma

Honoraria: Novartis, Merck Sharp & Dohme, Merck Serono, Roche

Consulting or Advisory Role: Novartis, Merck Sharp & Dohme, Y-Biologics, BMS Taiwan

Research Funding: Novartis, Boehringer Ingelheim

Travel, Accommodations, Expenses: Merck Serono

Jun Ma

Research Funding: Bristol Myers Squibb, Varian Medical Systems

No other potential conflicts of interest were reported.

APPENDIX

TABLE A1. Treatment of NPC Expert Panel Membership

Name	Affiliation or Institution	Role or Area of Expertise
Jun Ma (cochair)	Sun Yat-sen University Cancer Center, Guangzhou, China	Clinical Oncology
Yu-Pei Chen	Sun Yat-sen University Cancer Center, Guangzhou, China	Clinical Oncology
Jin-Ching Lin	Changhua Christian Hospital, Taiwan	Clinical Oncology
Jun-Lin Yi	National Cancer Center, Beijing, China	Clinical Oncology
Anthony T. C. Chan	The Chinese University of Hong Kong, Hong Kong, China	Medical Oncology
Brigitte Ma	The Chinese University of Hong Kong, Hong Kong, China	Medical Oncology
A. Dimitrios Colevas	Stanford University School of Medicine, Stanford, CA	Medical Oncology
Robert Haddad	Dana-Farber Cancer Institute, Boston, MA	Medical Oncology
Ying Sun (cochair)	State Key Laboratory of Oncology in South China, China	Radiation Oncology
Sue S. Yom	University of California San Francisco, San Francisco, CA	Radiation Oncology
Jin-Yi Lang	Sichuan Cancer Hospital & Institute, Chengdu, China	Radiation Oncology
Chao-Su Hu	Fudan University Shanghai Cancer Center, Shanghai, China	Radiation Oncology
Melvin L. K. Chua	National Cancer Centre Singapore, Singapore	Radiation Oncology
Joseph T. S. Wee	National Cancer Centre Singapore, Singapore	Radiation Oncology
Anne W. M. Lee	The University of Hong Kong, Hong Kong	Radiation Oncology
Quynh-Thu Le	Stanford University School of Medicine, Stanford, CA	Radiation Oncology
Nancy Lee	Memorial Sloan Kettering Cancer Center, New York, NY	Radiation Oncology
Shao Hui Huang	Princess Margaret Cancer Centre, Toronto, ON, Canada	Radiation Oncology
Jatin Shah	Memorial Sloan Kettering Cancer Center, New York, NY	Surgical Oncology
Alexander C. Whitley	Central Alabama Radiation Oncology, Montgomery, AL	Community Oncology (PGIN Representative)
Thomas J. Morgan	Monmouth, NJ	Patient Representative
Nofisat Ismaila	American Society of Clinical Oncology (ASCO), Alexandria, VA	ASCO Practice Guideline Staff (Health Research Methods)